Didanosine measurement by radioimmunoassay

被引：13

作者：

DeRemer, M

DAmbrosio, R

Morse, GD

机构：

[1] SUNY BUFFALO,DEPT PHARM PRACTICE,LAB ANTIVIRAL RES,AMHERST,NY 14260

[2] SUNY BUFFALO,DEPT MED,AMHERST,NY 14260

[3] UNIV ROCHESTER,SCH MED & DENT,AIDS CLIN TRIALS UNIT,ROCHESTER,NY

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1996年 / 40卷 / 06期

关键词：

D O I：

10.1128/AAC.40.6.1331

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Didanosine is commonly prescribed as monotherapy or as part of a combination regimen for patients with human immunodeficiency virus infection. The use of lower doses, either as part of a combination regimen or as a result of dose reduction secondary to clinical intolerance, requires that a sensitive assay method be available for either traditional or population-based pharmacokinetic evaluations. We evaluated a radioimmunoassay technique with a standard curve range of 0 to 100 ng/ml in human plasma, urine, and cerebrospinal fluid and assessed its accuracy and precision for use in pharmacokinetic studies.

引用

收藏

页码：1331 / 1334

页数：4

相关论文

共 18 条

[1]

ADAMS J, 1995, 2 NAT C HUM RETR REL, P146

[2] CLINICAL-PHARMACOLOGY OF 2',3'-DIDEOXYINOSINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN [J].

BALIS, FM ;

PIZZO, PA ;

BUTLER, KM ;

HAWKINS, ME ;

BROUWERS, P ;

HUSSON, RN ;

JACOBSEN, F ;

BLANEY, SM ;

GRESS, J ;

JAROSINSKI, P ;

POPLACK, DG .

JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :99-104

[3] PHARMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].

BARRY, M ;

HOWE, JL ;

ORMESHER, S ;

BACK, DJ ;

BRECKENRIDGE, AM ;

BERGIN, C ;

MULCAHY, F ;

BEECHING, N ;

NYE, F .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (05) :421-426

[4]

*BRIST MY SQUIBB L, 1994, VID PROD INF

[5] COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE COMPARED WITH ZIDOVUDINE ALONE IN HIV-1 INFECTION [J].

COLLIER, AC ;

COOMBS, RW ;

FISCHL, MA ;

SKOLNIK, PR ;

NORTHFELT, D ;

BOUTIN, P ;

HOOPER, CJ ;

KAPLAN, LD ;

VOLBERDING, PA ;

DAVIS, LG ;

HENRARD, DR ;

WELLER, S ;

COREY, L .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :786-793

[6] ONCE-DAILY ADMINISTRATION OF 2',3'-DIDEOXYINOSINE (DDI) IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME OR AIDS-RELATED COMPLEX - RESULTS OF A PHASE-I TRIAL [J].

COOLEY, TP ;

KUNCHES, LM ;

SAUNDERS, CA ;

RITTER, JK ;

PERKINS, CJ ;

MCLAREN, C ;

MCCAFFREY, RP ;

LIEBMAN, HA .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (19) :1340-1345

[7] IMPACT OF BIOAVAILABILITY ON DETERMINATION OF THE MAXIMAL TOLERATED DOSE OF 2',3'-DIDEOXYINOSINE IN PHASE-I TRIALS [J].

DRUSANO, GL ;

YUEN, GJ ;

MORSE, G ;

COOLEY, TP ;

SEIDLIN, M ;

LAMBERT, JS ;

LIEBMAN, HA ;

VALENTINE, FT ;

DOLIN, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1280-1283

[8] ANALYSIS OF POTENTIAL RISK-FACTORS ASSOCIATED WITH THE DEVELOPMENT OF PANCREATITIS IN PHASE-I PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX RECEIVING DIDANOSINE [J].

GRASELA, TH ;

WALAWANDER, CA ;

BELTANGADY, M ;

KNUPP, CA ;

MARTIN, RR ;

DUNKLE, LM ;

BARBHAIYA, RH ;

PITTMAN, KA ;

DOLIN, R ;

VALENTINE, FT ;

LIEBMAN, HA .

JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (06) :1250-1255

[9] PHARMACOKINETICS OF 2',3'-DIDEOXYADENOSINE AND 2',3'-DIDEOXYINOSINE IN PATIENTS WITH SEVERE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].

HARTMAN, NR ;

YARCHOAN, R ;

PLUDA, JM ;

THOMAS, RV ;

MARCZYK, KS ;

BRODER, S ;

JOHNS, DG .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) :647-654

[10] QUANTITATION OF DIDANOSINE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].

KNUPP, CA ;

STANCATO, FA ;

PAPP, EA ;

BARBHAIYA, RH .

JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 533 :282-290